Association Between Homocysteine and Vascular Calcification Incidence, Prevalence, and Progression in the MESA Cohort
- PMID: 32013703
- PMCID: PMC7033888
- DOI: 10.1161/JAHA.119.013934
Association Between Homocysteine and Vascular Calcification Incidence, Prevalence, and Progression in the MESA Cohort
Abstract
Background While elevated homocysteine has been associated with calcification in several studies, its importance as a cardiovascular risk factor remains unclear. This study examines the relationship between homocysteine and vascular and valve calcification in the MESA (Multi-ethnic Study of Atherosclerosis) cohort. Methods and Results MESA participants with baseline homocysteine measurements and cardiac computed tomography scans were included (N=6789). Baseline and follow-up assessment of vascular (coronary artery [CAC], descending thoracic aorta [DTAC]) and valve (aortic valve [AVC], mitral annular [MAC]) calcification was performed. Prevalence ratio/relative risk regression was used to assess the relationship of homocysteine with prevalent and incident calcification, and multivariable logistic regression was used to assess associations between homocysteine and calcification progression. Elevated homocysteine was associated with greater relative risk of prevalent and incident CAC and incident DTAC. We also identified a strong association between elevated homocysteine and CAC and DTAC progression. Elevated homocysteine was found to confer a >2-fold increased risk of severe CAC progression (defined as ΔCAC ≥100/year) and an ≈1.5-fold increased risk for severe DTAC progression (defined as ΔDTAC ≥100/year). Conclusions To our knowledge, this is the first study demonstrating an association between elevated homocysteine and both incidence and progression of coronary and extra-coronary vascular calcification. Our findings suggest a potential role for elevated homocysteine as a risk factor for severe vascular calcification progression. Future studies are warranted to further assess the utility of homocysteine as a biomarker for vascular calcification incidence and progression. Clinical Trial Registration https://www.clinicaltrials.gov/. Unique identifier: NCT00005487.
Keywords: calcification progression; cardiovascular disease; homocysteine; vascular calcification.
Similar articles
-
Matrix Gla protein and the long-term incidence and progression of coronary artery and aortic calcification in the Multi-Ethnic Study of Atherosclerosis.Atherosclerosis. 2024 May;392:117505. doi: 10.1016/j.atherosclerosis.2024.117505. Epub 2024 Mar 5. Atherosclerosis. 2024. PMID: 38527383
-
The novel inflammatory marker GlycA and the prevalence and progression of valvular and thoracic aortic calcification: The Multi-Ethnic Study of Atherosclerosis.Atherosclerosis. 2019 Mar;282:91-99. doi: 10.1016/j.atherosclerosis.2019.01.011. Epub 2019 Jan 24. Atherosclerosis. 2019. PMID: 30716566 Free PMC article.
-
Lipoprotein (a) and risk for calcification of the coronary arteries, mitral valve, and thoracic aorta: The Multi-Ethnic Study of Atherosclerosis.J Cardiovasc Comput Tomogr. 2021 Mar-Apr;15(2):154-160. doi: 10.1016/j.jcct.2020.06.002. Epub 2020 Jun 21. J Cardiovasc Comput Tomogr. 2021. PMID: 32620506 Free PMC article.
-
Multi-Ethnic Study of Atherosclerosis (MESA): JACC Focus Seminar 5/8.J Am Coll Cardiol. 2021 Jun 29;77(25):3195-3216. doi: 10.1016/j.jacc.2021.05.006. J Am Coll Cardiol. 2021. PMID: 34167645 Free PMC article. Review.
-
Vascular calcification: High incidence sites, distribution, and detection.Cardiovasc Pathol. 2024 Sep-Oct;72:107667. doi: 10.1016/j.carpath.2024.107667. Epub 2024 Jun 10. Cardiovasc Pathol. 2024. PMID: 38866090 Review.
Cited by
-
Cardiovascular Risk Assessment in Rheumatoid Arthritis: Accelerated Atherosclerosis, New Biomarkers, and the Effects of Biological Therapy.Life (Basel). 2023 Jan 23;13(2):319. doi: 10.3390/life13020319. Life (Basel). 2023. PMID: 36836675 Free PMC article. Review.
-
Exercise improves systemic metabolism in a monocrotaline model of pulmonary hypertension.Sports Med Health Sci. 2024 Mar 8;7(1):37-47. doi: 10.1016/j.smhs.2024.03.001. eCollection 2025 Jan. Sports Med Health Sci. 2024. PMID: 39649790 Free PMC article.
-
Identification of Disease-Relevant, Sex-Based Proteomic Differences in iPSC-Derived Vascular Smooth Muscle Cells.Int J Mol Sci. 2024 Dec 29;26(1):187. doi: 10.3390/ijms26010187. Int J Mol Sci. 2024. PMID: 39796045 Free PMC article.
-
Role of hyperhomocysteinemia in atherosclerosis: from bench to bedside.Ann Med. 2025 Dec;57(1):2457527. doi: 10.1080/07853890.2025.2457527. Epub 2025 Feb 3. Ann Med. 2025. PMID: 39898976 Free PMC article. Review.
-
Formyl-peptide receptor type 2 activation mitigates heart and lung damage in inflammatory arthritis.EMBO Mol Med. 2025 May;17(5):1153-1183. doi: 10.1038/s44321-025-00227-1. Epub 2025 Apr 3. EMBO Mol Med. 2025. PMID: 40181186 Free PMC article.
References
-
- Kullo IJ, Li G, Bielak LF, Bailey KR, Sheedy PF, Peyser PA, Turner ST, Kardia SL. Association of plasma homocysteine with coronary artery calcification in different categories of coronary heart disease risk. Mayo Clin Proc. 2006;81:177–182. - PubMed
-
- Shai I, Stampfer MJ, Ma J, Manson JE, Hankinson SE, Cannuscio C, Selhub J, Curhan G, Rimm EB. Homocysteine as a risk factor for coronary heart diseases and its association with inflammatory biomarkers, lipids and dietary factors. Atherosclerosis. 2004;177:375–381. - PubMed
-
- Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992;268:877–881. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
- HHSN268201500003I/HL/NHLBI NIH HHS/United States
- N01HC95159/HL/NHLBI NIH HHS/United States
- N01HC95160/HL/NHLBI NIH HHS/United States
- N01HC95161/HL/NHLBI NIH HHS/United States
- N01HC95162/HL/NHLBI NIH HHS/United States
- N01HC95163/HL/NHLBI NIH HHS/United States
- N01HC95164/HL/NHLBI NIH HHS/United States
- N01HC95165/HL/NHLBI NIH HHS/United States
- N01HC95166/HL/NHLBI NIH HHS/United States
- N01HC95167/HL/NHLBI NIH HHS/United States
- N01HC95168/HL/NHLBI NIH HHS/United States
- N01HC95169/HL/NHLBI NIH HHS/United States
- R01 HL071739/HL/NHLBI NIH HHS/United States
- UL1 TR000040/TR/NCATS NIH HHS/United States
- UL1 TR001079/TR/NCATS NIH HHS/United States
- UL1 TR001420/TR/NCATS NIH HHS/United States